9 clinical trials found.
-
ACNS1931: A Phase 3 Study of Selumetinib (NSC# 748727 IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1 non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
The purpose of the study is to determine and investigate the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine ...
Phase
-
DAY101-001/PNOC026/FIREFLY-1: A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with BRAF-Altered Recurrent or Progressive Low-Grade Glioma
The purpose of the study is to evaluate the safety and efficacy of oral pan-RAF inhibitor DAY101 in pediatric, adolescent, and young adult patients with ...Phase
-
A Pivotal Randomized Open-Label Study of Optune (TTFields 200khz) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
The purpose of the study is to test the effectiveness and safety of TTFields given to newly diagnosed glioblastoma patients, concomitantly with radiation therapy and ...Phase
-
Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas
The purpose of this research study is to provide ONC201 to patients with specific forms of brain cancer who cannot access ONC201 by participating in ... -
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors
The purpose of the study is to determine the overall response rates as well as safety and tolerability of olaparib in subjects with recurrent/progressive ...Phase
-
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1(NF1)
The purpose of the study is to find out the safety and efficacy of the drug selumetinib in treating patients with low-grade glioma. We want ...Phase
-
ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
ACNS1833 is a prospective randomized phase 3 study comparing selumetinib to CV in previously untreated LGG not associated with neurofibromatosis or BRAFV600E. This non-inferiority study ...Phase
-
ACNS1831: A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
The purpose of the study is to compare the efficacy of two treatments. The purpose is to determine whether the efficacy of treatment with selumetinib ...Phase
-
APEC1621SC: NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) SCREENING PROTOCOL
If you or your child have cancer that has become worse following treatment, or because no standard therapy exists for your type of cancer, you ...Phase
